A group of activists in Marin has sued the top county and state elections officials, alleging they have failed to maintain current and accurate voter rolls. The plaintiffs, members of an ...

Three Napa Valley water polo teams fell in the first round of the North Coast Section Division 2 playoffs on Wednesday. At ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Nico Chen has given his Buy rating due to a combination of factors including Eli Lilly’s strong revenue growth and the potential expansion of its diabetes medication Mounjaro. Chen recognizes ...

It provided little detail other than saying that Eli Lilly had shown it could “meet the present and projected national demand,” while acknowledging that patients could still see periodic ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

A San Rafael development firm has successfully challenged the historic eligibility status of an empty downtown bank, but plans for the site remain unclear. Monahan Pacific Corp. proposed that the ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide ...

Speaking shortly after his firm announced it “anticipates making £279m investment over three years” in the UK life sciences sector, Eli Lilly chief executive David Ricks warned that due to ...

Also Read: Eli Lilly’s Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron’s Dupixent In the LUCENT-3 trial, mirikizumab helped patients ...